litlas
ログインアカウント作成

Robert Knight

1996–2024 年に発表

57
論文数
19,214
被引用数
47
h 指数
53
i10 指数

被引用数

Robert Knight の年別被引用数1948 年: 被引用 2 件1989 年: 被引用 2 件1996 年: 被引用 7 件1997 年: 被引用 27 件1998 年: 被引用 44 件1999 年: 被引用 26 件2000 年: 被引用 56 件2001 年: 被引用 96 件2002 年: 被引用 72 件2003 年: 被引用 104 件2004 年: 被引用 88 件2005 年: 被引用 76 件2006 年: 被引用 110 件2007 年: 被引用 164 件2008 年: 被引用 168 件2009 年: 被引用 275 件2010 年: 被引用 234 件2011 年: 被引用 249 件2012 年: 被引用 152 件2013 年: 被引用 194 件2014 年: 被引用 129 件2015 年: 被引用 131 件2016 年: 被引用 154 件2017 年: 被引用 135 件2018 年: 被引用 121 件2019 年: 被引用 439 件2020 年: 被引用 473 件2021 年: 被引用 370 件2022 年: 被引用 279 件2023 年: 被引用 144 件2024 年: 被引用 219 件2025 年: 被引用 81 件2026 年: 被引用 1 件1949〜1988 年は被引用が無いため表示していません1990〜1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,743 件、この内訳の 29.9%イギリス: 引用元論文 385 件、この内訳の 6.6%ドイツ: 引用元論文 372 件、この内訳の 6.4%イタリア: 引用元論文 371 件、この内訳の 6.4%フランス: 引用元論文 321 件、この内訳の 5.5%スペイン: 引用元論文 228 件、この内訳の 3.9%カナダ: 引用元論文 213 件、この内訳の 3.6%中国: 引用元論文 193 件、この内訳の 3.3%オランダ: 引用元論文 170 件、この内訳の 2.9%スイス: 引用元論文 158 件、この内訳の 2.7%オーストラリア: 引用元論文 156 件、この内訳の 2.7%ギリシャ: 引用元論文 139 件、この内訳の 2.4%
0%29.9%その他 23.7%

機関

分野

  • Medicine79.4%
  • Biochemistry, Genetics and Molecular Biology16%
  • Immunology and Microbiology1.4%
  • Computer Science1.1%
  • Neuroscience0.3%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • その他1.5%

トピック

  • Multiple Myeloma Research and Treatments13%
  • Acute Myeloid Leukemia Research8.4%
  • Protein Degradation and Inhibitors7.9%
  • Bone health and treatments5%
  • Peptidase Inhibition and Analysis3.3%
  • Cancer Treatment and Pharmacology3.2%
  • その他59.2%

共著者

全論文

検索で開く
  1. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    著者: Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert H. Collins, Manish R. Patel, Arthur E. Frankel, Anthony S. Stein, Mikkael A. Sekeres, Ronan Swords, Bruno C. Medeiros, Christophe Willekens, Paresh Vyas, Alessandra Tosolini, Qiang Xu, Robert Knight, Katharine Yen, Sam Agresta, Stéphane de Botton, Martin S. Tallman - Blood 2017 被引用: 1,469

  2. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

    著者: Philip L. McCarthy, Sarah A. Holstein, Maria Teresa Petrucci, Paul G. Richardson, Cyrille Hulin, Patrizia Tosi, Sara Bringhen, Pellegrino Musto, Kenneth C. Anderson, D. Caillot, Francesca Gay, Philippe Moreau, Gérald Marit, Sin‐Ho Jung, Zhinuan Yu, Benjamin Winograd, Robert Knight, Antonio Palumbo, Michel Attal - Journal of Clinical Oncology 2017 被引用: 679

  3. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

    著者: Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R. Belch, Michèle Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie Cavenagh, Catarina Geraldes, Je‐Jung Lee, Christine Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell White, Daniel Binder, Kenneth Anderson, Jean-Paul Fermand, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin‐Haynes, Hervé Avet‐Loiseau, Cyrille Hulin, Thierry Façon - New England Journal of Medicine 2014 被引用: 786

  4. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery

    著者: Steven C. Katz, Ashley Moody, Prajna Guha, John C. Hardaway, Ethan Prince, Jason LaPorte, Mirela Stancu, Jill E. Slansky, Kimberly R. Jordan, Richard D. Schulick, Robert Knight, Abdul Saied, Vincent Armenio, Richard P. Junghans - Journal for ImmunoTherapy of Cancer 2020 被引用: 79

  5. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

    著者: Alan F. List, Gordon W. Dewald, John M. Bennett, Aristoteles Giagounidis, Azra Raza, Eric J. Feldman, Bayard L. Powell, Peter L. Greenberg, Deborah A. Thomas, Richard M. Stone, Craig B. Reeder, Kenton Wride, John Patin, M. Schmidt, Jerome B. Zeldis, Robert Knight - New England Journal of Medicine 2006 被引用: 1,317

  6. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    著者: Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal, H. Miles Prince, Jean‐Luc Harousseau, Anna Dmoszyńska, Jesús F. San Miguel, Andrzej Hellmann, Thierry Façon, Robin Foà, Alessandro Corso, Zvenyslava Masliak, Marta Olesnyckyj, Zhinuan Yu, John Patin, Jerome B. Zeldis, Robert Knight - New England Journal of Medicine 2007 被引用: 1,458

  7. Efficacy of Lenalidomide in Myelodysplastic Syndromes

    著者: Alan F. List, S. Kurtin, Denise J. Roe, Andrew J. Buresh, Daruka Mahadevan, Deborah Fuchs, Lisa M. Rimsza, Ruth Heaton, Robert Knight, Jerome B. Zeldis - New England Journal of Medicine 2005 被引用: 876

  8. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    著者: Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne‐Rauzy, Ghulam Mufti, Moshe Mittelman, Petra Muus, Peter A.W. te Boekhorst, Guillermo Sanz, Consuelo del Cañizo, Agnès Guerci‐Bresler, Lars Nilsson, Uwe Platzbecker, Michael Lübbert, Bruno Quesnel, Mario Cazzola, Arnold Ganser, David Bowen, Brigitte Schlegelberger, Carlo Aul, Robert Knight, John Francis, Tommy Fu, Eva Hellström‐Lindberg, for the MDS-004 Lenalidomide del5q Study Group - Blood 2011 被引用: 480

  9. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

    著者: Donna M. Weber, Christine Chen, Rubén Niesvizky, Michael Wang, Andrew R. Belch, Edward A. Stadtmauer, David S. Siegel, Ivan Borrello, S. Vincent Rajkumar, Asher Chanan‐Khan, Sagar Lonial, Zhinuan Yu, John Patin, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight - New England Journal of Medicine 2007 被引用: 1,235

  10. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

    著者: Paul G. Richardson, Edie Weller, Sagar Lonial, Andrzej Jakubowiak, Sundar Jagannath, Noopur Raje, David Avigan, Wanling Xie, Irene M. Ghobrial, Robert Schlossman, Amitabha Mazumder, Nikhil C. Munshi, David H. Vesole, Robin Joyce, Jonathan L. Kaufman, Deborah Doss, Diane Warren, Laura Lunde, Sarah Kaster, Carol Delaney, Teru Hideshima, Constantine S. Mitsiades, Robert Knight, Dixie‐Lee Esseltine, Kenneth C. Anderson - Blood 2010 被引用: 862

  11. Sotatercept in patients with osteolytic lesions of multiple myeloma

    著者: Abdulkadyrov Km, Galina Salogub, Nuriet K. Khuazheva, Matthew L. Sherman, Abderrahmane Laadem, Rachel Barger, Robert Knight, Shankar Srinivasan, Evangelos Terpos - British Journal of Haematology 2014 被引用: 127

  12. Expression of multiple slow myosin heavy chain genes reveals a diversity of zebrafish slow twitch muscle fibres with differing requirements for Hedgehog and Prdm1 activity

    著者: Stone Elworthy, Murray Hargrave, Robert Knight, Katharina Mebus, Philip W. Ingham - Development 2008 被引用: 153

  13. Myofiber stretch induces tensile and shear deformation of muscle stem cells in their native niche

    著者: Mohammad Haroon, Jenneke Klein‐Nulend, Astrid D. Bakker, Jianfeng Jin, Hadi Seddiqi, Carla Offringa, Gerard M.J. de Wit, Fabien Le Grand, Lorenzo Giordani, Karen Liu, Robert Knight, Richard T. Jaspers - Biophysical Journal 2021 被引用: 32

  14. Systems Analysis Reveals Ageing-Related Perturbations in Retinoids and Sex Hormones in Alzheimer’s and Parkinson’s Diseases

    著者: Simon Lam, Nils Hartmann, Rui Benfeitas, Cheng Zhang, Muhammad Arif, Hasan Türkez, Mathias Uhlén, Christoph Englert, Robert Knight, Adil Mardinoğlu - Biomedicines 2021 被引用: 24

  15. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

    著者: James R. Berenson, Alan Lichtenstein, Lisa A. Porter, Meletios Α. Dimopoulos, Rodolfo Bordoni, Saby George, Allan Lipton, Alan Keller, Oscar Ballester, Michael J. Kovacs, Hillary Blacklock, R. Bell, Joseph F. Simeone, Dirk J. Reitsma, M Heffernan, John J. Seaman, Robert Knight - Journal of Clinical Oncology 1998 被引用: 653

  16. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

    著者: Meletios Α. Dimopoulos, Christine Chen, Andrew Spencer, Rubén Niesvizky, Michel Attal, Edward A. Stadtmauer, Maria Teresa Petrucci, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, D. Weber - Leukemia 2009 被引用: 360

  17. Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

    著者: S. Vincent Rajkumar, Laura Rosiñol, Mohamad A. Hussein, John Catalano, W Wiktor-Jędrzejczak, Lela M. Lucy, Marta Olesnyckyj, Zhinuan Yu, Robert Knight, Jerome B. Zeldis, Joan Bladé - Journal of Clinical Oncology 2008 被引用: 345

  18. Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

    著者: Stephen Schey, Paul Fields, J. Blake Bartlett, Ian Clarke, G. Ashan, Robert Knight, Matthew Streetly, Angus Dalgleish - Journal of Clinical Oncology 2004 被引用: 313

  19. Tfap2 transcription factors in zebrafish neural crest development and ectodermal evolution

    著者: Trevor L. Hoffman, Anna L. Javier, Shelley Campeau, Robert Knight, Thomas F. Schilling - Journal of Experimental Zoology Part B Molecular and Developmental Evolution 2007 被引用: 125

  20. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

    著者: on behalf of the MDS-003 Study Investigators, Alan F. List, John M. Bennett, Mikkael A. Sekeres, B. Skikne, Tommy Fu, Jamile M. Shammo, Stephen D. Nimer, Robert Knight, Aristoteles Giagounidis - Leukemia 2013 被引用: 99

  21. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

    著者: Paul G. Richardson, Emily Blood, Constantine S. Mitsiades, Sundar Jagannath, Steven R. Zeldenrust, Melissa Alsina, Robert Schlossman, S. Vincent Rajkumar, K.R. Desikan, Teru Hideshima, Nikhil C. Munshi, Kathleen Kelly-Colson, Deborah Doss, Mary McKenney, Svetlana G. Gorelik, Diane Warren, Andrea Freeman, Rebecca L. Rich, Anfang Wu, Marta Olesnyckyj, Kenton Wride, William S. Dalton, Jerome B. Zeldis, Robert Knight, Edie Weller, Kenneth C. Anderson - Blood 2006 被引用: 522

  22. lockjawencodes a zebrafishtfap2arequired for early neural crest development

    著者: Robert Knight, Sreelaja Nair, Sarah Nelson, Ali Afshar, Yashar Javidan, Robert Geisler, Gerd-Joerg Rauch, Thomas F. Schilling - Development 2003 被引用: 194

  23. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

    著者: Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur Raje, Melissa Alsina, Irene M. Ghobrial, Robert Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura Lunde, John Feather, Michelle E. Maglio, Diane Warren, Dixil Francis, Teru Hideshima, Robert Knight, Dixie‐Lee Esseltine, Constantine S. Mitsiades, Edie Weller, Kenneth C. Anderson - Blood 2014 被引用: 183

  24. Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

    著者: Paul G. Richardson, Edie Weller, Sundar Jagannath, David Avigan, Melissa Alsina, Robert Schlossman, Amitabha Mazumder, Nikhil C. Munshi, Irene M. Ghobrial, Deborah Doss, Diane Warren, Laura Lunde, Mary McKenney, Carol Delaney, Constantine Mitsiades, Teru Hideshima, William S. Dalton, Robert Knight, Dixie‐Lee Esseltine, Kenneth C. Anderson - Journal of Clinical Oncology 2009 被引用: 162